Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blinded, Phase 2 trial in patients with PML due to JCPyV. Patients will receive treatment with a matched virus-specific T-cell product (CE VST01-JC) or placebo, and will then be monitored for response to therapy.


Clinical Trial Description

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by JC polyomavirus (JCPyV) occurring in immunocompromised patients who face a disease that is usually progressive and often fatal (Padgett 1971; Tan 2010). Annually, it is estimated that 4,000 people develop PML in the United States and Europe combined (NORD 2015). This is a randomized, double- blinded, Phase 2 trial in patients with PML due to JCPyV. Patients will receive treatment with a matched virus-specific T-cell product (CE VST01-JC) or placebo, and will then be monitored for response to therapy. The study is designed to evaluate whether CE-VST01-JC infusions will slow and ultimately halt neurological progression in patients with PML compared with placebo as evaluated by modified Rankin Score (mRS). ;


Study Design


Related Conditions & MeSH terms

  • Leukoencephalopathies
  • Leukoencephalopathy, Progressive Multifocal
  • Progressive Multifocal Leukoencephalopathy

NCT number NCT05541549
Study type Interventional
Source Cellevolve Bio Inc
Contact
Status Not yet recruiting
Phase Phase 2
Start date February 2023
Completion date April 2025

See also
  Status Clinical Trial Phase
Terminated NCT01211639 - Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy N/A
Completed NCT02004444 - JC Virus Reactivation in Multiple Sclerosis N/A
Recruiting NCT05849467 - Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy Phase 1
Recruiting NCT01730131 - Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Recruiting NCT04781309 - NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy Early Phase 1
Completed NCT02694783 - Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells Early Phase 1
Completed NCT01132053 - Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
Completed NCT03399981 - Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
Terminated NCT00746941 - Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) Phase 1/Phase 2
Completed NCT02895581 - Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy N/A
Recruiting NCT04453917 - Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy N/A
Recruiting NCT04091932 - Treatment of PD-1 Inhibitor in AIDS-associated PML Phase 2
Not yet recruiting NCT06276504 - Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection Phase 2/Phase 3